- Home
- IFRX
IFRX
InflaRx N.V.
as 12-20-2024 4:00pm EST
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
| Founded: | 2007 | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | 143.7M | IPO Year: | 2017 |
| Target Price: | $8.00 | AVG Volume (30 days): | 401.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.17 - $2.81 | Next Earning Date: | 11-08-2024 |
| Revenue: | $187,930 | Revenue Growth: | 177.12% |
| Revenue Growth (this year): | 435.15% | Revenue Growth (next year): | 180.44% |
Latest InflaRx N.V. News
IFRX Breaking Stock News: Dive into IFRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
Insider Monkey
a month ago
Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now?
MT Newswires
a month ago
InflaRx Says Severe Covid Drug Gets EU Panel's Positive Opinion; Shares Rise Pre-Bell
GlobeNewswire
a month ago
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
Simply Wall St.
a month ago
Prenetics Global And 2 Other US Penny Stocks To Watch
TipRanks
a month ago
InflaRx Reports Q3 2024 Financial Results and Progress
Simply Wall St.
a month ago
We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate
TipRanks
a month ago
InflaRx expects cash to fund operations into 2026
Compare IFRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IFRX InflaRx N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.